27 results on '"Robinson, Jennifer"'
Search Results
2. Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses
3. Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies
4. Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association
5. Roundtable discussion: Dietary fats in prevention of atherosclerotic cardiovascular disease
6. Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial
7. Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years
8. Red blood cell polyunsaturated fatty acids and mortality in the Women's Health Initiative Memory Study
9. A Randomized Study to Evaluate the Effect of an Inclisiran First Implementation Strategy vs Usual Care in Patients with ASCVD and Elevated Low-density Lipoprotein Cholesterol: Rationale and Design of the VICTORION-INITIATE Trial
10. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome
11. Benefits associated with achieving optimal risk factor levels for the primary prevention of cardiovascular disease in older men
12. Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients: Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
13. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study)
14. Future issues, public policy, and public awareness of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
15. Treatment of adults with Familial Hypercholesterolemia and evidence for treatment: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
16. In search of self-awareness: Results of the National Lipid Association 2010 Lipid Pulse Membership Survey
17. Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006
18. ETC-1002 Lowers LDL-Cholesterol and Beneficially Modulates Other Cardio-Metabolic Risk Factors in Hypercholesterolemic Subjects†
19. Age, Abdominal Obesity, and Baseline High-Sensitivity C-Reactive Protein Are Associated with Low-Density Lipoprotein Cholesterol, non–High-Density Lipoprotein Cholesterol, and ApoB Responses to Lipid-Lowering Therapy in Patients with Metabolic Syndrome and Moderately High/High Coronary Heart Disease Risk†
20. NLA Recommendations for the Diagnosis and Management of Familial Hypercholesterolemia in Children and Adults
21. Response by Sex to Statin and Ezetimibe Versus Statin Monotherapy: Pooled Analysis from 22,913 Hyperlipidemic Patients
22. Achievement of Specified Lipid and High-Sensitivity C-Reactive Protein Levels with Statin-Ezetimibe Versus Statin in Male and Female Patients Using Combined Data from 22,913 Patients
23. Another treatment gap: Restarting secondary prevention medications: The Women's Health Initiative
24. Effect of Metabolic Syndrome Factors and Insulin Resistance on Ezetimibe/Simvastatin and Atorvastatin Treatment Efficacy in Patients with Metabolic Syndrome and Moderately High/High CHD Risk
25. Dalcetrapib in High-Risk Patients with Type 2 Diabetes Mellitus and/or Metabolic Syndrome
26. Influence of Age/Gender/Race on the Efficacy of Ezetimibe/Simvastatin vs. Atorvastatin in Metabolic Syndrome Patients with Moderately High/High CHD Risk
27. Efficacy and Safety of Ezetimibe/Simvastatin vs. Atorvastatin in Patients with Hypercholesterolemia, Metabolic Syndrome, and Atherosclerotic Vascular Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.